Search hospitals > South Carolina > Greenville
Prisma Health Greenville Memorial Hospital
Claim this profileGreenville, South Carolina 29605
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
424 reported clinical trials
38 medical researchers
Summary
Prisma Health Greenville Memorial Hospital is a medical facility located in Greenville, South Carolina. This center is recognized for care of Parotid Gland Cancer, Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Prisma Health Greenville Memorial Hospital is involved with conducting 424 clinical trials across 737 conditions. There are 38 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Michael J Wagner, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage I
Stage II
2Cancer
Global LeaderStage IV
Stage I
Stage III
Top PIs
Ki Chung, MDPrisma Health Cancer Institute - Eastside6 years of reported clinical research
Expert in Cancer
Expert in Parotid Gland Cancer
97 reported clinical trials
199 drugs studied
Aniket SahaBI-LO Charities Children's Cancer Center8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
59 reported clinical trials
120 drugs studied
Jeffrey K. GiguerePrisma Health Cancer Institute - Faris8 years of reported clinical research
Studies Cancer
Studies Breast Cancer
26 reported clinical trials
64 drugs studied
Michael J Wagner, MDDana-Farber Cancer Institute5 years of reported clinical research
Studies Liposarcoma
Studies Round Cell Liposarcoma
15 reported clinical trials
19 drugs studied
Clinical Trials running at Prisma Health Greenville Memorial Hospital
Breast Cancer
Cancer
Bladder Cancer
Breast cancer
Parotid Gland Cancer
Stroke
Lung Cancer
Testicular cancer
Heart Failure
Testicular Carcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Prisma Health Greenville Memorial Hospital?
Where is Prisma Health Greenville Memorial Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Prisma Health Greenville Memorial Hospital accept?
What awards or recognition has Prisma Health Greenville Memorial Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.